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Abstract
Current treatment of hemophilia A (HemA) patients with repeated infusions of factor VIII (FVIII; abbreviated as F8 in
constructs) is costly, inconvenient, and incompletely effective. In addition, approximately 25 % of treated patients
develop anti-factor VIII immune responses. Gene therapy that can achieve long-term phenotypic correction without
the complication of anti-factor VIII antibody formation is highly desired. Lentiviral vector (LV)-mediated gene transfer
into hematopoietic stem cells (HSCs) results in stable integration of FVIII gene into the host genome, leading
to persistent therapeutic effect. However, ex vivo HSC gene therapy requires pre-conditioning which is highly
undesirable for hemophilia patients. The recently developed novel methodology of direct intraosseous (IO)
delivery of LVs can efficiently transduce bone marrow cells, generating high levels of transgene expression in
HSCs. IO delivery of E-F8-LV utilizing a ubiquitous EF1α promoter generated initially therapeutic levels of FVIII,
however, robust anti-FVIII antibody responses ensued neutralized functional FVIII activity in the circulation. In
contrast, a single IO delivery of G-FVIII-LV utilizing a megakaryocytic-specific GP1bα promoter achieved platelet-specific
FVIII expression, leading to persistent, partial correction of HemA in treated animals. Most interestingly, comparable
therapeutic benefit with G-F8-LV was obtained in HemA mice with pre-existing anti-FVIII inhibitors. Platelets is an ideal
IO delivery vehicle since FVIII stored in α-granules of platelets is protected from high-titer anti-FVIII antibodies; and that
even relatively small numbers of activated platelets that locally excrete FVIII may be sufficient to promote efficient clot
formation during bleeding. Additionally, combination of pharmacological agents improved transduction of LVs and
persistence of transduced cells and transgene expression. Overall, a single IO infusion of G-F8-LV can generate
long-term stable expression of hFVIII in platelets and correct hemophilia phenotype for long term. This approach has
high potential to permanently treat FVIII deficiency with and without pre-existing anti-FVIII antibodies.
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Background
Deficiency of blood clotting factor VIII (FVIII) results in
hemophilia A (HemA), a serious bleeding disorder. Current
treatment of HemA patients with repeated infusions of
FVIII is costly, inconvenient, and incompletely effective [1].
In addition, approximately 25 % of treated patients develop
anti-FVIII immune responses. Gene therapy that can
achieve long-term phenotypic correction without the com-
plication of anti-FVIII antibody formation represents a
highly desirable approach to treat HemA patients.
Previous phase I gene therapy clinical trials [2–4],
however, produced only transient, low-level FVIII ex-
pression due to inefficient gene delivery and induction
of immune responses to FVIII and/or gene therapy vec-
tors. The hematopoietic stem cells (HSCs) in bone mar-
row (BM) can serve as a significant target for stable
integration of therapeutic genes into the genome. Thera-
peutic levels of FVIII have been obtained by ex vivo gene
therapy using HSCs transduced by retroviral vectors car-
rying porcine FVIII combined with immune suppression
and busulfan [5, 6]. However, it is highly undesirable to
perform pre-conditioning for hemophilia patients.
It is demonstrated recently that in vivo gene transfer
can be successfully carried out by direct intraosseous
(IO) injection using several different vectors including
adeno-, retro-, and lenti-viral vectors (LVs) [7–10]. HSCs
can be efficiently transduced by these vectors and the
transgene expression was detected in both progenitors
and differentiated cell lineages [7, 8, 11]. This in vivo
protocol corrected BM defects for long-term in diseased
animals with Fanconi anemia [11]. Many drawbacks of
ex vivo gene therapy, including maintenance of stem cell
properties, low levels of engraftment, and side effects of
cytokine stimulation can be evaded [9, 10, 12]. Most im-
portantly, no pre-conditioning of the subject is required
for this approach, thus providing a novel strategy for
treating HemA.
In this concise review, we will discuss the recently de-
veloped novel approach of IO delivery of LVs to correct
hemA [10]. The benefit and limitations of using LVs
driven by ubiquitous and megakaryocyte-specific pro-
moters will be compared. The potential of the develop-
ment of this novel in vivo technology into clinically
feasible gene transfer protocol to treat hemA patients,
especially the clinically challenging patients with pre-
existing inhibitory antibodies will be discussed.
Review
Gene therapy vs. protein replacement therapy and other
therapies
Current treatment of hemophilia involves repeated infu-
sions of FVIII protein either as regular prophylaxis or
treatment during bleeding episodes. For severe patients,
the standard treatment consists of intravenous infusion
of factor VIII concentrates three times per week or
every other day [6, 7]. In addition, 25 % of the patients
develop inhibitory antibodies to FVIII following re-
peated infusions of FVIII. In recent years, efforts have
been made to improve the efficacy of protein replace-
ment therapy. One of the major successes is to prolong
the half-life of FVIII in circulation [13]. This is recently
achieved by either attaching polyethylene glycol (PEG)
to FVIII (PEGylated FVIII) [14, 15] or fusing a monomeric
Fc fragment of immunoglobulin G [16] or albumin [17] to
FVIII. Less frequent infusions of FVIII can be adminis-
tered to patients with these long lasting FVIII proteins.
Another successful approach is the development of a hu-
manized bispecific antibody (emicizumab; ACE910) that
binds to activated factor IX and factor X and mimics the
cofactor function of FVIII [18, 19]. In the first clinical trial,
the patients were given subcutaneous emicizumab weekly
for 12 weeks. The bleeding rate decreased significantly in
hemophilia patients with and without inhibitory anti-
bodies. Nonetheless, these therapies still need frequent in-
fusions of costly reagent and the long-term side effects
such as formation of antibodies against the products
themselves still need to be evaluated over time. Compared
to drug or protein therapy, gene therapy can achieve a
prolonged therapeutic effect with only one or a few treat-
ment for the lifetime.
Comparison between different viral vector-mediated gene
therapies for hemophilia
Recently, clinical trials of gene delivery of factor IX me-
diated by adenovirus-associated viral (AAV) vectors into
the liver generated encouraging results in hemophilia B
patients [20–22]. Furthermore, AAV-mediated, liver-
directed gene transfer of FVIII produced therapeutic
levels of gene expression in mice, dogs or macaques
[23–25]. Most recently, Biomarin reported encouraging
results of phase I/II clinical trial in a small number of
patients using AAV5-mediated gene transfer. Five out of
six high dose patients showed FVIII levels ranging be-
tween 4 and 60 % [26]. However it was noted there was
elevation of ALT liver enzyme levels and a prophylactic
corticosteroid therapy was given. The duration of clinical
benefit in the treated patients remains to be determined.
Furthermore, AAVs persist as episomal, concatemerized
vectors following in vivo gene transfer, whereas trans-
gene expression cassettes integrate into the host genome
following LV transduction, leading to long-term thera-
peutic effect. If successful, a single treatment of LV-
mediated gene therapy will be sufficient for life-long
effect. Additionally, one key advantage of LV over
traditional integrating gamma retroviral vectors is that
it can transduce both non-dividing and dividing cells,
leading to significantly increased efficiency targeting
primitive stem cells. Furthermore, addition of SIN
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LTR elements in self-inactivating (SIN)-LVs provided
improved safety by reducing transactivation capacity
[27], thus permitting inclusion of enhancer-less in-
ternal promoters in the transgene expression cassettes
[28]. In two recent clinical trials of ex vivo gene ther-
apy for Wiskott-Aldrich Syndrome (WAS) [29] and
Metachromatic leukodystrophy (MLD) [30], dramatic
clinical improvement was obtained without adverse
effects or aberrant clonal expansion. These results are
very encouraging, suggesting that LV may be a safer
gene therapy vector compared with traditional retro-
viral vector.
In vivo HSC gene therapy mediates sustained
transduction of HSCs in HemA mice
Although ex vivo HSC transduction/transplantation
protocols can successfully deliver FVIII into HemA
mice [6, 31], the procedure requires pre-conditioning
using potentially toxic, myelosuppressive agents. On
the contrary, IO delivery to transduce HSCs in vivo
can bypass this step, which is more desirable for
treating hemophilia patients. Furthermore, no signifi-
cant thrombocytopenia potentially induced by precon-
ditioning regimens is expected with the IO delivery
protocol. Additionally, compared with intravenous in-
fusion of LVs into the circulation, IO delivery directly
introduced LVs into the BM microenvironment, thus
significantly enhancing the transduction efficiency of
HSCs. In our recent report, a syringe pump was used
to slowly infuse VSV-G pseudotyped SIN-LV vectors
into the BM so that more vectors can be in better
contact with the resident cells to achieve high levels
of transduction [10] (Fig. 1a). When the BM cells
were examined 7 days post infusion of M-GFP-LV
driven by a ubiquitous MND promoter, a significant
GFP signal was observed in HSCs of the treated mice
(Fig. 1b). Furthermore, GFP expression persisted in
10–50 % HSCs up to 160 days (Fig. 1c&d), indicating
that IO delivery of LVs has achieved efficient trans-
duction of primitive progenitor cells in BM. More-
over, lower numbers of transduced cells were initially
found in the untreated leg compared to the treated
leg (Fig. 1b), whereas at later times, similar numbers
of transduced cells were obtained at both sites
(Fig. 1c), indicating that the transduced HSCs were trans-
ferred from treated to untreated BM sites over time. These
results clearly demonstrated that IO LV delivery mediates
sustained transduction of hematopoietic stem/progenitor
cells [10, 32].
Comparison between IO deliveries of F8-LVs driven by
two different promoters
As mentioned in the introduction, one of the major
complications of hemophilia treatment is the forma-
tion of anti-FVIII inhibitory antibodies. For achieving
successful gene therapy, it is essential to prevent or
evade anti-FVIII immune responses. For this purpose,
platelet has been considered as a potential gene trans-
fer vehicle to ectopically express FVIII because: (1)
FVIII can be released to promote clot formation
when the circulating platelets are recruited to and ac-
tivated at the injury sites, (2) when needed, ectopic
FVIII can be provided by circulating platelets that are
produced daily from megakaryocytes in BM, (3) in
Fig. 1 GFP expression in BM cells following IO infusion of M-GFP-LV. a Schematic of IO infusion of vectors into the mice with an infusion speed
of 10 μl/min, which was precisely controlled by a programmable microfluidics syringe pump. b C57BL/6 mice were intraosseously delivered with
M-GFP-LV (1.1 × 108 ifu/animal, n = 6) on day 0. BM cells were isolated from treated or untreated legs and GFP expression in Lin−Sca1+c-Kit+ HSCs
were examined on day 7 by flow cytometry. c C57BL/6 mice were given IO infusion of M-GFP-LV (1.1 × 108 ifu; n = 8) on day 0. GFP expression in
Lin−Sca1+c-Kit+ HSCs of treated and untreated legs was evaluated on day 124. d C57BL/6 mice were given IO infusion of M-GFP-LV (8.8 × 108 ifu/
animal; n = 10) or PBS (20 μl/animal, mock; n = 5) on day 0. Long-term GFP expression in Lin−Sca1+c-Kit+ HSCs was detected on day 160. This figure is
reproduced from Ref [10]
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particular, platelet FVIII stored in α-granules is not neu-
tralized by anti-FVIII antibodies in the circulation [33, 34].
Previous reports showed that platelet-restricted expression
of FVIII using megakaryocyte-specific promoters (glyco-
protein (Gp) αIIb [31, 33, 34], Gp1bα [35] and plate-
let factor 4 [36]) can partially correct hemophilia
phenotype in transgenic mice or in lethally irradiated
HemA mice treated with ex vivo gene therapy. Ec-
topic expression of FVIII in platelets locally delivers
protein and concomitantly evades anti-FVIII immune
responses in treating HemA.
In our recent study [10], it was found that IO delivery
of E-F8-LV using a ubiquitous human elongation
factor-1α (EF1α) promoter into BMs of hemA mice effi-
ciently transduced HSCs and produced initial high-
levels of FVIII. However, a robust immune response to
FVIII was induced, eliminating functional FVIII in the
circulation (Fig. 2a). In contrast, a single IO delivery of
G-F8-LV using a human megakaryocytic-specific GP1bα
promoter produced persistent platelet-specific expression
of FVIII (Fig. 2b), leading to persistent, partial correction
of HemA phenotype (Fig. 2c). Interestingly, we did not de-
tect hFVIII activity or anti-hFVIII antibody in plasma up
to 160 days post treatment (Fig. 2d), implying that little or
no hFVIII expression was secreted into the circulation.
These results are consistent with previous work using the
Gp1bα promoter to direct FVIII expression in platelets
[35, 37]. It was shown that FVIII co-localized with VWF
and stored in α-granules of platelets via a regulated secre-
tary pathway [34].
Fig. 2 Comparison of hFVIII levels in plasma and/or platelets after a single IO infusion of E-F8-LVs and G-F8-LVs. a HemA mice were intraosseously
infused with E-F8-LV (5 × 107 ifu/animal, n = 4) or PBS (20 μl/animal, mock, n = 3) on day 0. Plasma samples were collected and hFVIII activity and
anti-FVIII antibodies were measured by aPTT and Bethesda assay, respectively. No FVIII activity or anti-FVIII antibody was detected in the PBS treated
control mice (data not shown). b-d HemA mice were given IO infusion of G-F8-LV (2.2 × 107 ifu/animal or 2.2 × 106 ifu/animal) or PBS (20 μl/animal,
mock) on day 0. b Platelets were isolated from peripheral blood of high (n = 8) or low (n = 5) titer G-F8-LV treated or mock (n = 3) mice.
hFVIII expression levels in CD42d+ platelets were evaluated by flow cytometry on day 27, 62, 84, 112 and 160. c HemA phenotype correction of G-F8-LV
treated mice was monitored by tail clip assay on day 35, 118, and 160 (n= 4–7/group). The average blood loss of untreated HemA mice was set as 100 %.
Wild-type C57BL/6 mice were used as positive controls. * P< 0.05. d Plasma samples were collected from high titer G-F8-LV treated (n= 10) or mock
(n= 3) mice, and hFVIII activity and anti-FVIII antibodies were measured by aPTT and Bethesda assay, respectively. This figure is reproduced from Ref [10]
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A single IO infusion of G-F8-LV produced persistent
expression of FVIII in platelets
Following IO delivery, up to 3 % of platelets expressed
FVIII driven by platelet-specific promoters [10] (Fig. 3a).
The average hFVIII antigen level evaluated by ELISA was
1 mU per 1 × 108 platelets, a level comparable to previ-
ously described transgenic animals expressing platelet
FVIII by chromogenic assay [35]. Our results clearly
showed that Gp1bα specifically drives FVIII expression in
platelets following IO infusion and that FVIII stored in
platelets corrects the HemA phenotype. It should be
noted that platelet delivered FVIII may produce different
kinetics of clot formation temporally and spatially from
plasma FVIII as see in the laser injury mouse model [38].
However, enhancement of clot formation with platelet-
targeted gene therapy has been demonstrated previously
using a range of injury models including tail bleeding
assay, survival assay, digital cuticular bleeding assay, and
ferric chloride-induced arterial injury model [31, 33–35].
Our recent results [10] clearly showed that even low levels
of FVIII released from platelets could partially correct the
HemA phenotype. Incorporation of variant FVIII cDNAs
with higher expression levels including codon optimized
FVIII [24, 25, 39] may further increases the thera-
peutic effect of IO delivery targeting platelets. Addition-
ally, although platelet-stored FVIII is proven to restore
hemostasis, the mouse models have their limitations.
Human clinical trials will be the ultimate demonstration
that a reduction in incidence of spontaneous bleeds (such
as joint bleeds) can be achieved.
FVIII ectopically expressed and stored in platelets corrects
HemA mice with pre-existing high-titer inhibitor antibodies
Much effort has been devoted to investigate effective
means to overcome the complication of inhibitory anti-
body formation to FVIII, including the development of
immune modulation protocols (see recent Review [40])
or generation of tissue-specific vectors (including pro-
moter and envelope) or delivery of vectors via specific
route [41, 42] to induce tolerance to FVIII. Shi and col-
leagues [33, 43] reported that pre-conditioning and ex
vivo gene transfer of HSCs expressing platelet FVIII im-
proved hemostasis in HemA mice with pre-existing in-
hibitory antibodies. Our investigation [10] demonstrates
that a single IO delivery of G-F8-LV generated signifi-
cant functional FVIII activity (Fig. 3b). Most importantly,
Fig. 3 hFVIII expression in platelets of G-F8-LV treated inhibitor HemA mice corrected their hemophilia A phenotype. Inhibitor HemA mice were
established by repeated intraperitoneal injection (3×/week for 2 weeks) of 3U rhFVIII into 10- to 12-week-old HemA mice. These inhibitor HemA
mice were then intraosseously infused with G-F8-LV (2.2 × 107 ifu/animal) or PBS (20 μl/animal, mock) on day 0. a Platelets were isolated from
peripheral blood and marked with CD42d+, and their GFP expression levels at 5 months post infusion. b Platelets from LV-treated (n = 5) and
mock (n = 3) mice and lysed. The resulting lysate was examined for hFVIII expression level by ELISA on day 27 post infusion. c The phenotypic
correction of G-F8-LV treated HemA inhibitor mice (n = 7) was examined by tail clip assays on day 160 post infusion. The average blood loss of
untreated HemA (n = 10) mice was set as 100 %. Wild-type C57BL/6 mice (n = 8) were used as positive controls. * P < 0.05, ** P < 0.005. This figure
is reproduced from Ref [10]
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persistent, partial therapeutic effect was obtained despite
of the presence of pre-existing high-titer anti-FVIII anti-
bodies (Fig. 3c). These results indicate that FVIII ectopi-
cally expressed and stored in α-granules of the platelets
and released at the injury sites represents a promising
strategy to HemA patients with high-titer inhibitors, in-
cluding individuals who were previously excluded from
gene therapy clinical trials.
Use pharmacological approaches to enhance in situ
transduction efficiency of HSCs following IO delivery of
LVs into the BM
Furthermore, following IO delivery of LVs in immune-
competent mice, we found lymphocyte infiltrates in BM
and gradual decreases of transduced cells, which are
similar to the innate and adaptive responses observed
from LV transduction in hepatocytes [44–46]. By admin-
istering a short course of combination drug treatment
with Dexamethasone (Dex) and AntiCD8α antibody, we
were able to achieve better initial transduction and reduce
the potential of generating CTLs and other adaptive im-
mune responses [47]. These agents in combination syner-
gistically augmented LV transduction.
Conclusions
Although long-lasting factor concentrates have im-
proved efficacy of protein replacement therapy, and
FVIII-mimetic bispecific antibody is promising as an
alternative treatment especially for patients with in-
hibitory antibodies, these therapies require frequent,
at least weekly dosing of costly reagents. With the re-
cent successes in clinical trials of AAV-mediated gene
transfer, it is anticipated that gene therapy will be the
next generation medicine for hemophilia treatment.
The potential obstacles of AAV-mediated gene ther-
apy include unpredictable events of transaminase ele-
vation, potential requirement of repeated treatment
that cannot be performed due to pre-existing anti-
AAV immune responses, and the prohibitively high
cost of high-titer vectors needed for hemA treatment.
The recently developed novel strategy of IO delivery of
F8-LVs [10] can efficiently transduce bone marrow cells
and express FVIII in HSCs without the requirement of
using potentially toxic, myelosuppressive pre-conditioning
methods and the risk of inducing thrombocytopenia. Al-
though ubiquitous expression of FVIII and secretion into
the circulation induced high-titer inhibitory antibody pro-
duction and eliminated functional FVIII activity, a single
IO infusion of G-F8-LVs driven by a megakaryocyte-
specific promoter produced long-term stable expression
of hFVIII in platelets and corrected hemophilia phenotype
for long term. Most significantly, this strategy is proven
successful in HemA mice with pre-existing inhibitory anti-
bodies. Use of combination of pharmacological agents
further enhanced the persistence of transduced cells and
transgene expression. IO delivery is already a clinically
proven method for drug delivery. IO LV delivery can be
easily developed for human clinical trials for hemophilia
patients with and without pre-existing inhibitory anti-
bodies. This new simple novel protocol has the potential
for a single treatment to achieve life-long therapeutic ef-
fect for hemophilia.
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